BackgroundThis review and meta-analysis examined published evidence of peptide receptor radionuclide therapy (PRRT) re-treatment efficacy safety in patients with advanced neuroendocrine tumors (NETs).MethodsEmbase, MEDLINE, MEDLINE In-Progress, Cochrane CENTRAL were searched (database inception–present) to identify PRRT adults NETs previously treated 177Lu- and/or 90Y-PRRT. Progression-free sur...

Abstract This review describes the basic principles of radiometal-theranostics and its dawn based on development positron-emitting 86 Y Y-labeled radiopharmaceuticals to quantify biodistribution dosimetry 90 analogue therapeutics. The nuclear inorganic (including cross section data, irradiation, radiochemical separation recovery) led preclinical clinical evaluation citrate EDTMP complexes yield...

Prostate-specific membrane antigen (PSMA) continues to be an active biomarker for small-molecule PSMA-targeted imaging and therapeutic agents for prostate cancer and various non-prostatic tumors that are characterized by PSMA expression on their neovasculature. One of the challenges for small-molecule PSMA inhibitors with respect to delivering therapeutic payloads is their rapid renal clearance...

BACKGROUND Systemic therapy with radionuclides may be used for the treatment of patients with painful skeletal metastases owing to its efficacy, low cost and low toxicity. Imported radionuclides for pain palliation, like Strontium-89 are expensive; particularly for developing countries. In the Indian scenario, Samarium-153 (Sm-153) is produced in our own reactors and as a result, it is readily ...

Abstract—[Tris (1,10-phenanthroline) lanthanum(III)] trithiocyanate is a new compound that has shown high ability for stopping the synthesis of DNA and also acting as a photosensitizer. Nowadays, the radiation dose assessment resource (RADAR) method is known as the most common method for absorbed dose calculation. 177Lu was produced by (n, gamma) reaction in a research reactor. Lu-PL3 was prepa...

Background: Osteosarcoma (OS) represents the most common primary bone tumor in humans and companion dogs, being practically phenotypically identical. There is a need for effective treatments to extend survival of patients with OS. Here, we examine dosimetry beagle dogs cross-reactivity human tissues novel antibody, IF3, that targets insulin growth factor receptor type 2 (IGF2R), which overexpre...